Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — Probiodrug — FY2016 Earnings Presentation

30 slides from Vivoryon Therapeutics's earnings presentation, Mar 30, 2017

  1. Slide 1: The 2016 financial year – Full year results

    The 2016 financial year Full year results Halle (Saale), 30 March 2017 Konrad Glund Hendrik Liebers Inge Lues Frank Weber CEO CFO CDO CMO

  2. Slide 2: Important notice and disclaimer

    Important no*ce and disclaimer This Presenta*on has been prepared and issued by Probiodrug AG (the “Company”) and has not been independently verified by any third party. No representa*on or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projec*o

  3. Slide 3: Content

    Content 1. Corporate introduc0on 2. Results 2016 3. Outlook 4. Q & A 3

  4. Slide 4: Longstanding track-record and renowned investor base

    Longstanding track-­‐record and renowned investor base Brief history Major investors (> 3%) ¡ 1997: Founda*on, pioneered a new class of an*-­‐diabe*cs (glip*ns) – partnerships with Merck & Co, Ferring and Novar*s ¡ 2004: Sold diabetes franchise to OSI Pharmaceu*cals – proceeds par*ally returned to

  5. Slide 5: Alzheimer's Disease: growing burden, no cure

    Alzheimer's Disease: growing burden, no cure Worldwide demen0a popula0on will triple Alzheimer's Disease introduc0on in the next 30 years* ¡ Leading cause of demen*a, ul*mately CAGR leading to death +3% 131 ¡ Large burden on families 47 ¡ Growing cost for society ¡ Available treatments marginall

  6. Slide 6: Probiodrug's differentiated approach

    Probiodrug’s differen0ated approach Probiodrug targets toxic structures in Alzheimer's Disease Considera0ons* ¡ Probiodrug and others Most new drugs have focused on Abeta forma0on or Abeta/plaque clearance have progressed insights on Abeta and its role in AD ¡ Abeta has a physiological func*on ¡ P

  7. Slide 7: pGlu-Abeta - N-modified Abeta

    pGlu-­‐Abeta -­‐ N-­‐modified Abeta Jawhar, S., Wirths, O., Bayer, T.A. JBC 286, 45, 2011 7

  8. Slide 8: Target pGlu-Abeta: small molecule approach (QC inhibitor)

    Target pGlu-­‐Abeta: small molecule approach (QC inhibitor) Probiodrug was first to discover the role of QC and has full ownership of broad target IP Jawhar, S., Wirths, O., Bayer, T.A. JBC 286, 45, 2011; modified 8

  9. Slide 9: Target pGlu-Abeta: antibody approach

    Target pGlu-­‐Abeta: an*body approach Probiodrug’s complementary approach with a pGlu-­‐Abeta specific an0body Jawhar, S., Wirths, O., Bayer, T.A. JBC 286, 45, 2011; modified 9

  10. Slide 10: Emerging landscape of disease modifyers in AD

    Emerging landscape of disease modifyers in AD Immunotherapy Modula0ng Abeta produc0on ¡ Verubecestat (MK-­‐8931): Phase 3 Passive } Beta secretase inhibitor, prodromal AD ¡ Aducanumab (BIIB037): Phase 3 ¡ AZD3293: Phase 2/3 } Beta secretase inhibitor, mild AD } early AD ¡ E2609: Phase 2 ¡ Cr

  11. Slide 11: Focused proprietary pipeline

    Focused proprietary pipeline Pre-­‐ Product Phase 1 Phase 2 clinical PQ912 ¡ Small molecule QC inhibitor Trial ongoing PBD-­‐C06 ¡ pGlu-­‐Abeta specific monoclonal an*body PQ1565 ¡ Small molecule QC inhibitor Clinical proof of concept 11

  12. Slide 12: The Probiodrug Share

    The Probiodrug Share KEY INFORMATION SHAREHOLDER (> 3%)* § ISIN: DE0007921835 § WKN: 792183 § Ticker Symbol: PBD § Type of shares: Bearer shares § Number of shares: 8,186,735 § Stock exchange: Euronext Amsterdam § Liquidity Provider: Kempen & Co. § Lis*ng Agent: Kempen & Co. § First trading

  13. Slide 13: Content

    Content 1. Corporate introduc*on 2. Results 2016 3. Outlook 4. Q & A 13

  14. Slide 14: Highlights 2016

    Highlights 2016 2016 ¡ Favourable results of chronic toxicology studies with Glutaminyl Cyclase (QC) inhibitor PQ912 announced ¡ Encouraging combina*on data of PQ912 with pGlu-­‐Abeta specific an*body PBD-­‐C06 generated ¡ Innova*ve Phase 2 study design of PQ912 in early Alzheimer’s disease presen

  15. Slide 15: Highlights 2016 – cont.

    Highlights 2016 – cont. 2016 ¡ Capital raise of EUR 14.9 million executed in October 2016 ¡ Cash and cash equivalents of EUR 21.9 million as of 31 December 2016 ¡ Net loss of EUR 13.9 million compared with EUR 13.5 million in 2015 – in line with company expecta*ons Post-­‐period Highlights ¡ The

  16. Slide 16: Key financial figures (according to IFRS)

    Key financial figures (according to IFRS) In EUR k 2016 2015 Earnings, Financial and Net Assets Posi*on Opera*ng loss -­‐13,777 -­‐13,393 Net loss for the period -­‐13,891 -­‐13,505 Equity (end of the year) 16,376 16,133 Equity ra*o (end of the year) (in %) 73.2 73.8 Balance sheet total (end of the ye

  17. Slide 17: Details of the Financial Results (according to IFRS)

    Details of the Financial Results (according to IFRS) Net loss net loss § Net loss in line with expecta*ons § Opera*ng loss primarily driven by R&D expenses § Increase in opera*ng expenses reflects opera*ng loss EUR 13,777 k primarily investments in PQ912 financial loss EUR 114 k § Financial loss l

  18. Slide 18: Operational Review (1)

    Opera*onal Review (1) Pipeline Update PQ912 ¡ First QC-­‐inhibitor being tested in humans ¡ In preceding Phase 1 study with healthy young and elderly volunteers shown to be safe, well tolerated and revealed high QC-­‐inhibi*on ¡ SAPHIR is a randomized, double-­‐blind mul*-­‐center study } Run in

  19. Slide 19: Operational Review (2)

    Opera*onal Review (2) PBD-­‐C06 ¡ Monoclonal an*body targe*ng pGlu-­‐Abeta, while leaving non-­‐toxic forms of Abeta untouched ¡ Currently in preclinical stage ¡ Successfully humanized and de-­‐immunized ¡ For the first *me for an an*-­‐pGlu-­‐Abeta-­‐an*body approach PBD-­‐C06 has not only shown

  20. Slide 20: Operational Review (3)

    Opera*onal Review (3) Publica0ons/ Presenta0ons ¡ March 2016: Two oral presenta*ons en*tled “The pyroglutamate modifica*on of toxic A-­‐beta resulted in new therapeu*c approaches: Inhibitors of glutaminyl cyclase and highly specific an*bodies – A status report” and “Phagocy*c characteriza*on and ther

  21. Slide 21: Operational Review (4)

    Opera*onal Review (4) Publica0ons ¡ May 2016: Two poster en*tled “Quan*ta*ve Analysis of truncated Aβ pep*de substrates of glutaminyl cyclase in human CSF samples using LC-­‐MS/MS,” and “Determina*on of Aβ Oligomers using a Flow Cytometry-­‐Förster Resonance Energy Transfer (FRET) method,” presente

  22. Slide 22: Operational Review (5)

    Opera*onal Review (5) Publica0ons ¡ September 2016: New findings for Probiodrug’s Glutaminyl Cyclase – inhibitor in an inflamma*on animal model were presented at the Summer Fron*ers Symposium 2016 ‘Systems Biology of Innate Immunity’, Nijmegen, The Netherlands and the 6th European Workshop on Lipid M

  23. Slide 23: Operational Review (6)

    Opera*onal Review (6) Publica0ons ¡ November 2016: First results of a preclinical study in an AD mouse model with the pyroglutamate-­‐3 Abeta (pGlu3-­‐Abeta)-­‐specific an*body mPBD-­‐C06, comparing versions with and without a muta*on elimina*ng complement ac*va*on were presented as a poster at the

  24. Slide 24: Operational Review (7)

    Opera*onal Review (7) IP ¡ In 2016, IP posi*on further strengthened by important patent applica*ons being granted } Patents US 9,156,907 and JP 5,828,762 covering an*body program targe*ng pyroglutamate Abeta (pGlu-­‐Abeta, also N3pG Abeta) in the US and in Japan, method as well as composi*on of ma

  25. Slide 25: Corporate Review

    Corporate Review Execu0on of a capital increase via accelerated bookbuild on October 6, 2016 ¡ Increase of share capital from EUR 7,442,487 to EUR 8,186,735, issuing 744,248 new shares ¡ Represen*ng appr. 10% of the issued share capital at the *me of the placement ¡ Gross proceeds of EUR 14.9 mil

  26. Slide 26: Content

    Content 1. Corporate introduc*on 2. Results 2016 3. Outlook 4. Q & A 26

  27. Slide 27: Outlook

    Outlook Mid-­‐term focus of Probiodrug’s business ac0vi0es can be summarised as follows: ¡ Con*nuing the clinical development of PQ912, in par*cular generate ini*al pa*ent study data in 2017 and start long-­‐term treatment, ¡ Con*nuing the development of PBD-­‐C06, ¡ Con*nuing the development of

  28. Slide 28: News flow (selection)

    News flow (selec&on) 2014 2015 2016 2017 ¡ First pa*ent enrolled in PQ912 Phase PQ912 results of long term tox ¡ PQ912 Phase 2a ✔ ✔ ¡ 2a “SAPHIR” study at leading studies SAPHIR results Alzheimer Center in Amsterdam ¡ Addi*onal data on Glutaminyl Cyclases ¡ Promising an*-­‐inflammatory effect ¡ P

  29. Slide 29: Financial Calendar

    Financial Calendar ¡ 12 May 2017 Interim Management Statement Q1 2017 ¡ 13 June 2017 Annual General Mee*ng of Shareholders ¡ 31 August 2017 Interim Report, half year results 2017 ¡ 30 November 2017 Interim Management Statement Q3 2017 29

  30. Slide 30: Content

    Content 1. Corporate introduc*on 2. Results 2016 3. Outlook 4. Q & A 30

Probiodrug — FY2016 Earnings Presentation on 6ix